AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03369067 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dexcom CGM G5
Description: The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes
Study NCT03369067 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Subcutaneous Insulin Infusion
Description: Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
Study NCT01928342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day
Study NCT01928342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without coenzyme A.
Study NCT01938105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nimotuzumab+chemoradiotherapy
Description: Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~--------------------------------------------------------------------------------
Study NCT03729011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volatile agent
Description: Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
Study NCT03729011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
Study NCT02308332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eviplera
Description: switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
Study NCT04178512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control
Description: prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
Study NCT02443922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 2mg qam
Study NCT02443922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100mg qam
Study NCT02443922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed
Study NCT02443922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin as prescribed
Study NCT01050010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: dedicated extremity MRI
Study NCT02349568 — intervention group
Intervention type: PROCEDURE
Intervention: High risk group
Description: Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
Study NCT02349568 — intervention group
Intervention type: PROCEDURE
Intervention: Intermediate risk group
Description: Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
Study NCT00871351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
Study NCT00871351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
Study NCT00871351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
Study NCT00871351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
Study NCT01289041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT01213043 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolastin-C, 60 mg/kg
Description: 60 mg/kg weekly infusion of Prolastin-C for 8 weeks
Study NCT01213043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolastin-C, 120 mg/kg
Description: 120 mg/kg weekly infusion of Prolastin-C for 8 weeks
Study NCT04162990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle remodeling Intervention
Description: Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
Study NCT04162990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Does Comparator: regular treatment
Description: Participants in this group would be treated as usual, which contained the healthy education.
Study NCT00782977 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal oxygen therapy
Description: Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
Study NCT00782977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen therapy
Description: Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
Study NCT02959671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower Anterior EXD-952 Self-ligating Brackets
Description: Placement of EXD-952 Self-ligating Brackets on mandibular incisors
Study NCT03169192 — intervention group
Intervention type: DRUG
Intervention: Zoledronic Acid
Description: intravenous injections once every 3 months
Study NCT01175772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytophosphan, Celecoxib, Methotrexate
Description: Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly
Study NCT02655471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir and Zidovudine
Description: Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
Study NCT02887989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
Study NCT02887989 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Health and Wellness Channel
Description: Relaxing content broadcast passively on the patient in-room television channel.
Study NCT01886638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Study NCT01567943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Behavioral reinforcement for alcohol abstinence
Study NCT02831179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02831179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PI
Study NCT02831179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: given PO
Study NCT02831179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02831179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03355963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
Study NCT03355963 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A 50 units
Description: The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
Study NCT03355963 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A 100 units
Description: The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
Study NCT02617264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPOT
Description: Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
Study NCT02468609 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ultralow-Dose-CT
Description: Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
Study NCT01033292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201
Description: IV infusion, 5.6 mg/kg
Study NCT04290065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
Study NCT01464008 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
Study NCT01129531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
Study NCT01129531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AGN-214868
Description: Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
Study NCT03550430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alpha/delta neurofeedback
Description: neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
Study NCT03550430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: beta/theta neurofeedback
Description: neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
Study NCT03550430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diary completion
Description: completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
Study NCT02423590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatorsen (OGX-427)
Description: Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
Study NCT02423590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite
Study NCT02423590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite
Study NCT02423590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.
Study NCT02423590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.
Study NCT02030912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 doses of amoxicillin daily for 7 days
Study NCT02030912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 doses of minocycline daily for five days
Study NCT02030912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2 doses of placebo daily for five days
Study NCT04944394 — intervention group
Intervention type: OTHER
Intervention: online questionnaire
Description: Administration of an online questionnaire (Limesurvey platform) at M0~- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected.
Study NCT04944394 — intervention group
Intervention type: OTHER
Intervention: questionnaire survey
Description: A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
Study NCT04560205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation.
Study NCT02483013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whitening dentifrices
Description: Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
Study NCT02483013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
Study NCT01432015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosaprepitant
Description: Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
Study NCT01432015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
Study NCT01432015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: One pill administered on days 1-3 in conjunction with Fosaprepitant.
Study NCT01432015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo
Description: 100 cc of IV placebo administered on day in conjunction with Aprepitant
Study NCT03661996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
Study NCT03661996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine without epinephrine
Description: 15 mL lidocaine intra-articular injection
Study NCT01005940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Mandibular advancement device made to subject specific specifications
Study NCT03661996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastoGel
Description: Cooling Device
Study NCT03661996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Ice Water Pump
Description: Cooling Device
Study NCT03746743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: score for neonatal sepsis
Description: score for neonatal sepsis to predict morbidity
Study NCT03785457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Trunk Extension
Description: Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
Study NCT03785457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Trunk Extension
Description: Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
Study NCT04639921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: positive test followed by gluten-free diet
Description: DBPCFC with gluten
Study NCT04639921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: positive test followed by gluten-free diet
Description: DBPCFC with gluten
Study NCT04639921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04639921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00807521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Single high dose bolus of dexamethasone before surgery
Study NCT00807521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dexamethasone
Study NCT02519647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation with Gliderite
Description: Tracheal intubation with Gliderite
Study NCT02519647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation with S-guide
Description: Tracheal intubation with S-guide
Study NCT00584701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
Study NCT03659643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EEG with SPR analysis
Description: qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
Study NCT04639518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm formulas with HMO
Description: Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
Study NCT04639518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm formulas without HMO
Description: Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
Study NCT01083147 — intervention group
Intervention type: DEVICE
Intervention: FORESEE HOME
Description: Home Monitoring
Study NCT01989286 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: The posture, motor development and balance are going to be assessed.
Study NCT04539119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1\*10\^3/L.